atezolizumab based treatment | anti-PD-(L)1 | durvalumab based treatment | nivolumab based treatment | pembrolizumab based treatment | sintilimab based treatment | anti-PD-(L)1 | Immune checkpoint association | nivolumab plus ipilimumab | ||||
atezolizumab plus bevacizumab | atezolizumab plus cabozantinib | camrelizumab based treatment | durvalumab plus bevacizumab | nivolumab alone | pembrolizumab alone | pembrolizumab plus lenvatinib | sintilimab | Tislelizumab | durvalumab plus tremelimumab | nivolumab plus ipilimumab | nivolumab plus ipilimumab plus SoC |